AKT1 and chronic myelogenous leukemia, BCR-ABL1 positive: The downregulation of miR-10a in chronic myeloid leukemia CD34+ cells increases USF2-mediated cell growth [37] and increases the cisplatin resistance of lung adenocarcinoma circulating tumor cells via targeting PIK3CA in the PI3K/Akt pathway [38].